NCT03615235
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
Active, Not Recruiting
Not specifiedAll AgesObservationalWake Forest University Health SciencesInvestigator-initiated
~5,000 participants
Updated 2026-05-26 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 18 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to death-censored renal allograft failure from the UNOS database
Measured over up to 4.5 years
Conditions
Where it's being run
18 sites across 14 statesNew York3
Maryland2
North Carolina2
Alabama1
California1
Florida1
Georgia1
Massachusetts1
Study leadership
- Barry I. Freedman, MD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences
- David M. Reboussin, PhD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences
- Paul L. Kimmel, MD · STUDY_DIRECTOR · Natl Institute of Diabetes, Digestive & Kidney Diseases
- Marva Moxey-Mims, MD · STUDY_CHAIR · Children's Natl Health System; George Washington Univ Sch of Med and Health Serv
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Living kidney donors with self-reported recent African ancestry (defined as African American, Afro-Caribbean, Hispanic black or African) will be eligible for inclusion.
Exclusion
Participants who are unable or unwilling to provide informed consent.
What this trial measures
- Time to death-censored renal allograft failure from the UNOS databaseup to 4.5 years
Time from receipt of kidney transplant to death-censored renal allograft failure. Measured in days.